Dr. Cotter explores emerging technologies that may enhance the evaluation, risk stratification, and monitoring of melanoma and atypical melanocytic lesions. He reviews tools ranging from AI-augmented lesion assessment to molecular testing and liquid biopsy approaches, highlighting how these innovations may complement traditional clinical and histopathologic evaluation.
Topics Covered
- AI-augmented assessment of atypical moles
- Electrical impedance spectroscopy for lesion risk stratification
- Using 31-gene expression profiling to assess melanoma metastasis risk
- Informing sentinel lymph node biopsy decisions
- Circulating tumor DNA as an emerging liquid biopsy approach
- Monitoring high-risk skin cancers for recurrence and treatment response
Explore Related Resources
